OCCULOGIX REPORTS RESULTS OF MACULAR DEGENERATION STUDY

Eye drug developer OccuLogix has reported mixed results of a study for the treatment of age-related macular degeneration, a degenerative eye disease.

The company reported that preliminary analysis of data from a Phase III clinical trial using its Rheo system did not demonstrate a statistically significant difference in the mean change of best spectacle-corrected visual acuity, applying the early treatment diabetic retinopathy scale between treated and placebo groups at 12 months post-baseline.